Gt Biopharma Stock Shares Owned By Insiders
| GTBP Stock | USD 3.15 0.30 10.53% |
GT Biopharma fundamentals help investors to digest information that contributes to GT Biopharma's financial success or failures. It also enables traders to predict the movement of GTBP Stock. The fundamental analysis module provides a way to measure GT Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GT Biopharma stock.
GTBP | Shares Owned By Insiders |
GT Biopharma Company Shares Owned By Insiders Analysis
GT Biopharma's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current GT Biopharma Shares Owned By Insiders | 6.66 % |
Most of GT Biopharma's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GT Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
GTBP Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for GT Biopharma is extremely important. It helps to project a fair market value of GTBP Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since GT Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of GT Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of GT Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 6.66% of GT Biopharma are shares owned by insiders. This is 56.13% lower than that of the Biotechnology sector and 53.03% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 33.99% higher than that of the company.
GTBP Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GT Biopharma's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GT Biopharma could also be used in its relative valuation, which is a method of valuing GT Biopharma by comparing valuation metrics of similar companies.GT Biopharma is currently under evaluation in shares owned by insiders category among its peers.
GT Biopharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of GT Biopharma from analyzing GT Biopharma's financial statements. These drivers represent accounts that assess GT Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of GT Biopharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 979.7M | 4.7M | 31.6M | 28.2M | 10.3M | 9.8M | |
| Enterprise Value | 990.4M | 18.0M | 52.6M | 22.7M | 9.3M | 8.8M |
GT Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, GT Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to GT Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
GTBP Fundamentals
| Return On Equity | -1.05 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | (5.74 M) | ||||
| Shares Outstanding | 2.16 M | ||||
| Shares Owned By Insiders | 6.66 % | ||||
| Shares Owned By Institutions | 15.67 % | ||||
| Number Of Shares Shorted | 2.73 K | ||||
| Price To Book | 0.62 X | ||||
| EBITDA | (13.58 M) | ||||
| Net Income | (7.6 M) | ||||
| Cash And Equivalents | 23.73 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 58 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.78 X | ||||
| Book Value Per Share | 3.85 X | ||||
| Cash Flow From Operations | (8.85 M) | ||||
| Short Ratio | 0.41 X | ||||
| Earnings Per Share | (7.01) X | ||||
| Target Price | 150.0 | ||||
| Beta | 0.62 | ||||
| Market Capitalization | 6.79 M | ||||
| Total Asset | 14.11 M | ||||
| Retained Earnings | (682.07 M) | ||||
| Working Capital | 7.42 M | ||||
| Net Asset | 14.11 M |
About GT Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GT Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GT Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GT Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.